Table 1 Demographics, diagnoses and characterization of angioedema
From: Review of icatibant use in the Winnipeg Regional Health Authority
| Category | n | Stratification | Count (% of n) | p-value (*< 0.05) |
|---|---|---|---|---|
| Presentations with icatibant dispensation | 23 | NA | 23 (100) | NA |
| Diagnosis | 23 |
HAE nC1INH |
10 (43) 10 (43) | |
| ACEIIAE | 11 (48) | |||
| Not yet diagnosed | 1 (4) | |||
| tPA-induced angioedema | 1 (4) | |||
| Sex | 23 | Any diagnosis | ||
| Male | 8 (35) | 0.11 | ||
| Female | 15 (65) | |||
| 10 | HAE | |||
| Male | 3 (30) | 0.95 | ||
| Female | 7 (70) | |||
| 13 | Non-HAE | |||
| Male | 5 (38) | 0.87 | ||
| Female | 8 (62) | |||
| Age | 23 | All—median years (range) | 57.5 (35–82) | NA |
| 10 | HAE—median years (range) | 52 (35–60) | 0.02* | |
| 13 | Non-HAE—median years (range) | 73.5 (37–82) | ||
| Localization of angioedema | 23 | Any diagnosis | NA | |
| Face/oropharolarynx | 16 (70) | |||
| Abdominal | 9 (39) | |||
| Cutaneous | 6 (26) | |||
| 10 | HAE | |||
| Face/oropharolarynx | 4 (40) | |||
| Abdominal | 8 (80) | |||
| Cutaneous | 1 (10) | |||
| 13 | Non-HAE | |||
| Face/oropharolarynx | 12 (92) | |||
| Abdominal | 1 (8) | |||
| Cutaneous | 5 (38) | |||
| History of allergy | 6 | HAE | 1 (17) | |
| Non-HAE | 5 (83) | |||
| ACEI prescribed | 11 | Fosinopril | 2 (18) | |
| Lisinopril | 3 (27) | |||
| Perindopril | 3 (30) | |||
| Quinapril | 1 (10) | |||
| Ramipril | 2 (20) | |||